Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology.

STUDY OBJECTIVE: To determine why, despite 122 randomised controlled trials, there is no consensus about whether the selective serotonin reuptake inhibitors or tricyclic and related antidepressants should be used as first line treatment of depression. DESIGN: Systematic review of all RCTs comparing selective serotonin reuptake inhibitors and tricyclic or heterocyclic antidepressants. MAIN RESULTS: The shortcomings identified in the 122 trials were as follows: (1) there was inadequate description of randomisation, (2) the outcomes used were mainly observer rated measurements of depression, and studies failed to use quality of life measures or perform economic evaluations, (3) doses of tricyclic antidepressants were inadequate, (4) generalisability of studies was poor (including a reliance on secondary care settings and inadequate follow up), and (5) there were statistical shortcomings such as low statistical power, failure to use intention to treat analyses, and the tendency to make multiple comparisons. CONCLUSIONS: Future RCTs should be designed to inform policy makers and address these methodological shortcomings.

[1]  D. Klein,et al.  The clinical measurement of depressive disorders. , 1987 .

[2]  G. Wilkinson,et al.  Outcome of Depression in Psychiatric Settings , 1994, British Journal of Psychiatry.

[3]  D. Nutt,et al.  Selective serotonin reuptake inhibitors: meta‐analysis of discontinuation rates , 1994, International clinical psychopharmacology.

[4]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[5]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[6]  D. Spiegelhalter,et al.  Quality of life measures in health care. I: Applications and issues in assessment. , 1992, BMJ.

[7]  H. Kick,et al.  Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study. , 1990, Pharmacopsychiatry.

[8]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[9]  P. Linkowski,et al.  Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. , 1995, Sleep.

[10]  F. Song,et al.  Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide , 1994, BMJ.

[11]  J H Greist,et al.  Comparison of computer- and interviewer-administered versions of the Diagnostic Interview Schedule. , 1987, Hospital & community psychiatry.

[12]  S. Kasper,et al.  Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta‐analysis , 1995, International clinical psychopharmacology.

[13]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[14]  A. Stewart,et al.  The MOS short-form general health survey. Reliability and validity in a patient population. , 1988, Medical care.

[15]  I. Anderson,et al.  Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis , 1995, BMJ.

[16]  A. Ravindran,et al.  The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression , 1995 .

[17]  F. Meurgey,et al.  The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. , 1994, Journal of affective disorders.

[18]  J. Fudge,et al.  A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. , 1990, Journal of affective disorders.

[19]  P. Peer,et al.  Continuation and maintenance therapy with antidepressive agents , 1990, Pharmaceutisch Weekblad.

[20]  C. Blacker,et al.  Depressive Disorder in Primary Care , 1987, British Journal of Psychiatry.

[21]  S. Montgomery,et al.  The Prophylactic Efficacy of Fluoxetine in Unipolar Depression , 1988, British Journal of Psychiatry.

[22]  A. Eggen,et al.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? , 1991, BMJ.

[23]  F. Song,et al.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. , 1993, BMJ.

[24]  G. Rudolf,et al.  A double‐blind study of the comparative antidepressant effect of paroxetine and amitriptyline , 1989, Acta psychiatrica Scandinavica. Supplementum.

[25]  S M Gore,et al.  Quality of life measures in health care. III: Resource allocation. , 1992, BMJ.

[26]  P. Bebbington,et al.  What Price Depression? , 1994, British Journal of Psychiatry.

[27]  M. Hotopf,et al.  Are SSRIs a Cost-Effective Alternative to Tricyclics? , 1996, British Journal of Psychiatry.

[28]  D. A. Johnson.  Depression: Treatment compliance in general practice , 1981, Acta psychiatrica Scandinavica. Supplementum.

[29]  I. Anderson,et al.  The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants , 1994, Journal of psychopharmacology.

[30]  D. Spiegelhalter,et al.  Quality of life measures in health care. II: Design, analysis, and interpretation. , 1992, BMJ.

[31]  M. Hotopf,et al.  Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity , 1997, British Journal of Psychiatry.

[32]  Morton B. Brown,et al.  Depression in stroke rehabilitation , 1993, Biological Psychiatry.

[33]  L. Robins,et al.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. , 1981, Archives of general psychiatry.

[34]  R G Priest,et al.  Recognition and management of depression in general practice: consensus statement. , 1992, BMJ.

[35]  S. Pocock.  A perspective on the role of quality-of-life assessment in clinical trials. , 1991, Controlled clinical trials.

[36]  G. Lewis,et al.  Assessing psychiatric disorder with a human interviewer or a computer. , 1994, Journal of epidemiology and community health.

[37]  D. Cicchetti,et al.  Reliability of depression and associated clinical symptoms. , 1983, Archives of general psychiatry.

[38]  R. Priest.  Measurement and Classification of Psychiatric Symptoms , 1975 .

[39]  G Lewis,et al.  Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers , 1992, Psychological Medicine.

[40]  A. Stewart,et al.  The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. , 1989, JAMA.

[41]  Interferon beta‐lb in the treatment of multiple sclerosis , 1995, Neurology.

[42]  T. Suurmeijer,et al.  A Study of the Unidimensionality and Cumulativeness of the MOS Short-Form General Health Survey , 1994, Psychological reports.

[43]  J. G. Edwards,et al.  Comparative effects of fluoxetine and amitriptyline on cardiac function. , 1988, British journal of clinical pharmacology.

[44]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.